Troy Wichterman Sells 877 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 877 shares of the business's stock in a transaction on Monday, July 7th. The stock was sold at an average price of $22.27, for a total value of $19,530.79. Following the transaction, the chief financial officer directly owned 185,808 shares in the company, valued at $4,137,944.16. This trade represents a 0.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, June 10th, Troy Wichterman sold 1,042 shares of BioLife Solutions stock. The stock was sold at an average price of $23.70, for a total value of $24,695.40.
• On Wednesday, May 28th, Troy Wichterman sold 583 shares of BioLife Solutions stock. The shares were sold at an average price of $22.46, for a total value of $13,094.18.

BioLife Solutions Price Performance

BioLife Solutions stock traded down $0.22 during mid-day trading on Wednesday, hitting $22.33. 352,995 shares of the company were exchanged, compared to its average volume of 421,076. BioLife Solutions, Inc. has a 12-month low of $18.70 and a 12-month high of $29.55. The business's 50 day simple moving average is $22.45 and its two-hundred day simple moving average is $24.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.73 and a quick ratio of 3.74. The company has a market capitalization of $1.06 billion, a P/E ratio of -77.00 and a beta of 1.79.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. BioLife Solutions had a negative return on equity of 0.66% and a negative net margin of 11.81%. The firm had revenue of $23.94 million for the quarter, compared to analysts' expectations of $22.22 million. Analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Wall Street Zen lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, BioLife Solutions has a consensus rating of "Moderate Buy" and a consensus target price of $31.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BLFS. T. Rowe Price Investment Management Inc. acquired a new position in shares of BioLife Solutions in the first quarter worth about $30,789,000. Raymond James Financial Inc. bought a new stake in BioLife Solutions in the fourth quarter valued at about $20,664,000. Massachusetts Financial Services Co. MA bought a new stake in BioLife Solutions in the fourth quarter valued at about $19,805,000. Royal Bank of Canada increased its holdings in BioLife Solutions by 762.8% in the first quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider's stock valued at $15,948,000 after buying an additional 617,320 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in BioLife Solutions in the fourth quarter valued at about $11,113,000. Institutional investors and hedge funds own 93.24% of the company's stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.